Funding will support commercial deployment, clinical adoption and further development and enhancement of the Hyperspectral Intelligence® platform for AI-assisted surgery
Angelini Ventures Managing Director Tanja Dowe joins Hypervision Surgical’s Board of Directors
Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, is participating in Hypervision Surgical’s oversubscribed £17 million Series A round. Hypervision Surgical (“Hypervision”) is a UK-based pioneer in real-time hyperspectral imaging for surgery.
The funding, led by Heal Capital with participation from Angelini Ventures, IP Group, and Daycrest among others, aims to accelerate the commercial deployment of Hypervision’s Hyperspectral Intelligence® platform, expanding its clinical adoption and transforming the company’s next-generation hyperspectral sensing technology – co-developed with Imec, a global leader in the development of semiconductor and spectral sensing technologies – in a scalable, cloud-enabled platform for AI-assisted surgery.
The Hyperspectral Intelligence® imaging platform captures information beyond what the human eye – and conventional surgical cameras – can perceive. By combining hyperspectral sensing with AI-driven analytics, the technology enables real-time, quantitative insights into tissue physiology during surgery. This has the potential to fundamentally improve intraoperative decision-making, reduce complications, and establish a new data-driven standard for surgical care.
The company’s goal is to integrate Hyperspectral Intelligence® into laparoscopic, robotic, microscopic and endoscopic surgical platforms, making it possible to read more accurately the data in the hundreds of millions of surgeries performed each year.
Michael Ebner, CEO and Co-Founder of Hypervision Surgical, said: “This Series A marks a major milestone in our mission to power surgical intelligence through hyperspectral vision. By combining advanced spectral sensing with cloud-enabled AI analytics, we are building a new intelligence layer in surgery – giving surgeons real-time insights into tissue that were previously impossible to access.”
As part of the financing, Tanja Dowe will join Hypervision’s Board of Directors.
Tanja Dowe, Managing Partner at Angelini Ventures, said: “We believe Hypervision Surgical is redefining what is possible in surgical visualization. Hypervision’s technology has the potential to significantly improve surgical outcomes and patient safety. We are excited to support the team as they scale this breakthrough platform and bring it into clinical practice.”
The financing round also includes existing investors HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures as well as strategic investment from the SINC Fund managed by SAGES Ingenuity, the for-profit innovation arm subsidiary of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), a leading global surgical society, and Macmillan Cancer Support, the UK’s leading cancer charity – further validating HVS approach from both clinical and patient communities.
Explore AITechPark for the latest Artificial Intelligence News advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!